<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25874951</article-id><article-id pub-id-type="pmc">4398323</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0122330</article-id><article-id pub-id-type="publisher-id">PONE-D-14-57905</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage</article-title><alt-title alt-title-type="running-head">Aspirin-Induced Enteropathy and Rebamipide</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Toshio</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Takeuchi</surname><given-names>Toshihisa</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Handa</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sakata</surname><given-names>Yasuhisa</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tanigawa</surname><given-names>Tetsuya</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shiba</surname><given-names>Masatsugu</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Naito</surname><given-names>Yuji</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Higuchi</surname><given-names>Kazuhide</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fujimoto</surname><given-names>Kazuma</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yoshikawa</surname><given-names>Toshikazu</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arakawa</surname><given-names>Tetsuo</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Department of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Green</surname><given-names>John</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University Hospital Llandough, UNITED KINGDOM</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>YN has received research grants from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd and Takeda Pharmaceutical Co., Ltd. KH has received research grants and speaker&#x02019;s fee from Otsuka Pharmaceutical Co., Ltd. TA has received research grants from Eisai Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd provided rebamipide and identical placebo. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: TW YN KH KF TY TA. Performed the experiments: TW T. Takeuchi OH YS T. Tanigawa. Analyzed the data: MS. Contributed reagents/materials/analysis tools: TW T. Tanigawa. Wrote the paper: TW TA.</p></fn><corresp id="cor001">* E-mail: <email>watanabet@med.osaka-cu.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>4</issue><elocation-id>e0122330</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Watanabe et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Watanabe et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0122330.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Low-dose aspirin (LDA) frequently causes small bowel injury. While some drugs have been reported to be effective in treating LDA-induced small intestinal damage, most studies did not exclude patients with mild damage thought to be clinically insignificant.</p></sec><sec id="sec002"><title>Aim</title><p>We conducted a multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy of a high dose of rebamipide, a gastroprotective drug, for LDA-induced moderate-to-severe enteropathy.</p></sec><sec id="sec003"><title>Methods</title><p>We enrolled patients who received 100 mg of enteric-coated aspirin daily for more than 3 months and were found to have more than 3 mucosal breaks (i.e., erosions or ulcers) in the small intestine by capsule endoscopy. Eligible patients were assigned to receive either rebamipide 300 mg (triple dose) 3 times daily or placebo for 8 weeks in a 2:1 ratio. Capsule endoscopy was then repeated. The primary endpoint was the change in the number of mucosal breaks from baseline to 8 weeks. Secondary endpoints included the complete healing of mucosal breaks at 8 weeks and the change in Lewis score (an endoscopic score assessing damage severity) from baseline to 8 weeks.</p></sec><sec id="sec004"><title>Results</title><p>The study was completed by 38 patients (rebamipide group: n = 25, placebo group: n = 13). After 8 weeks of treatment, rebamipide, but not placebo, significantly decreased the number of mucosal breaks (p = 0.046). While the difference was not significant (p = 0.13), the rate of complete mucosal break healing in the rebamipide group (32%, 8 of 25) tended to be higher than that in the placebo group (7.7%, 1 of 13). Rebamipide treatment significantly improved intestinal damage severity as assessed by the Lewis score (p = 0.02), whereas placebo did not. The triple dose of rebamipide was well tolerated.</p></sec><sec id="sec005"><title>Conclusions</title><p>High-dose rebamipide is effective for the treatment of LDA-induced moderate-to-severe enteropathy.</p></sec><sec id="sec006"><title>Trial Registration</title><p>UMIN Clinical Trials Registry <ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&#x00026;action=brows&#x00026;type=summary&#x00026;recptno=R000004171&#x00026;language=J">UMIN000003463</ext-link>
</p></sec></abstract><funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec007"><title>Introduction</title><p>While it is prescribed widely for the primary or secondary prevention of cardiovascular or cerebrovascular disease [<xref rid="pone.0122330.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0122330.ref003" ref-type="bibr">3</xref>], low-dose aspirin (LDA) increases the risk of gastrointestinal ulceration and bleeding. In the last decade, concerns over this adverse effect of LDA focused mainly on the upper gastrointestinal tract. However, several studies used video capsule endoscopy (VCE) to show that LDA frequently causes injury to small bowel [<xref rid="pone.0122330.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0122330.ref005" ref-type="bibr">5</xref>], inducing intestinal bleeding and anemia [<xref rid="pone.0122330.ref006" ref-type="bibr">6</xref>]. Thus, LDA-induced enteropathy has recently been recognized as clinically significant.</p><p>Several clinical trials were performed with the aim of overcoming this adverse effect of LDA on the small intestine, and some drugs were shown to effectively heal LDA-induced small intestinal damage [<xref rid="pone.0122330.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0122330.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0122330.ref008" ref-type="bibr">8</xref>]. However, these studies did not exclude patients with mild damage thought to be clinically insignificant. Furthermore, few randomized double-blind trials supporting the efficacy of treatments for LDA-induced enteropathy have been reported.</p><p>Rebamipide (2-(4-chlorobenzoylamino-3-[2(1H)-quinolinon-4-yl] propionic acid)), a gastroprotective drug, has been clinically proven to effectively heal gastric ulcers [<xref rid="pone.0122330.ref009" ref-type="bibr">9</xref>] and prevent non-steroidal anti-inflammatory drug (NSAID)-induced gastroduodenal damage [<xref rid="pone.0122330.ref010" ref-type="bibr">10</xref>]. Recent studies using VCE have shown that rebamipide also has anti-ulcer effects in the small intestine, preventing both LDA- and NSAID-induced enteropathy in healthy volunteers [<xref rid="pone.0122330.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0122330.ref012" ref-type="bibr">12</xref>]. This suggests that rebamipide may also be effective in treating LDA-induced enteropathy. Importantly, Akamatsu et al. reported that rebamipide exhibited anti-ulcer effects via direct local penetration from inside the stomach to the gastric mucosa, but not via systemic delivery after absorption in the gastrointestinal tract [<xref rid="pone.0122330.ref013" ref-type="bibr">13</xref>]. Therefore, the ulcer-healing effect of rebamipide on the small intestine appears weak at the standard dose of 300 mg/day, so a higher dose is thought to be needed to successfully treat small intestine damage, especially LDA-induced severe enteropathy. Although the dose of rebamipide currently approved for gastric ulcer and gastritis is 300 mg/day, doses up to 900 mg/day were investigated in a phase II dose-finding study conducted in Japan, and no safety problems were noted. Hence, we conducted a multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy of triple-dose rebamipide in the treatment of LDA-induced moderate-to-severe small intestinal damage.</p></sec><sec sec-type="materials|methods" id="sec008"><title>Methods</title><p>The protocol of this trial and the supporting CONSORT checklist are available as supporting information; see <xref rid="pone.0122330.s001" ref-type="supplementary-material">S1 CONSORT Checklist</xref> and <xref rid="pone.0122330.s002" ref-type="supplementary-material">S1 Protocol</xref>.</p><sec id="sec009"><title>Ethical approval</title><p>Before the start of the study, the Institutional Review Board of each participating institution reviewed and approved the protocol: The ethics committee of the Osaka City University Graduate School of Medicine (approval number, 1619); The ethics committee of the Osaka Medical College (approval number, 705): The ethics committee of the Kyoto Prefectural University of Medicine (approval number, C-633); and The ethics committee of the Saga Medical School (approval number, 2012-10-01). Written informed consent was obtained from all participants</p></sec><sec id="sec010"><title>Study design</title><p>This Cytoprotection by REbamipide on Aspirin-induced Mid-GI damage (CREAM) study was a multicenter, randomized, double-blind, placebo-controlled trial conducted to assess the efficacy and safety of triple-dose rebamipide for LDA-induced moderate-to-severe small intestinal damage. The study was carried out at 4 medical centers (Osaka City University Hospital, Osaka Medical College Hospital, Kyoto Prefectural Medical University Hospital, and Saga University Hospital) in Japan from February 2011 through January 2014. The study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. This trial was registered in the UMIN Clinical Trials Registry as UMIN000003463.</p><p>Eligible patients were assigned to receive either rebamipide 300 mg 3 times daily or placebo for 8 weeks in a 2:1 allocation ratio. Randomization was achieved by the minimization method, and stratified by site of enrollment and use of concomitant antiplatelet drugs. After 8 weeks of treatment with rebamipide or placebo, VCE was performed to assess the impact of treatment on small intestinal damage.</p></sec><sec id="sec011"><title>VCE procedure</title><p>VCE was performed using the PillCam SB2 (Given Imaging, Ltd, Yoqneam, Israel). Patients fasted for 12 h before swallowing the capsule. Fluids were permitted 2 h later, followed by a light meal another 2 h later. Data were collected for up to 8 h after capsule ingestion. After 8 h, the sensor array and recording device were removed. The VCE digital image stream was then reviewed by 4 experts (Tetsuya T, Toshihisa T, OH, and YS). Since it is difficult to definitively distinguish between erosions and ulcers (because VCE cannot accurately assess either lesion size or depth), we combined them into a single category of injury (mucosal breaks).</p><p>In addition, the severity of LDA-induced enteropathy was assessed with the Lewis score (LS) [<xref rid="pone.0122330.ref014" ref-type="bibr">14</xref>], a capsule endoscopic grading system of small intestinal mucosal inflammation and damage. The detailed methods of calculating the LS have been previously described [<xref rid="pone.0122330.ref014" ref-type="bibr">14</xref>]. Small bowel inflammatory changes were categorized into 3 groups according to the LS: normal or clinically insignificant change (LS &#x0003c;135), mild mucosal inflammatory change (LS 135&#x02013;790), and moderate or severe change (LS &#x0003e;790).</p></sec><sec id="sec012"><title>Patients</title><p>Male or female outpatients were eligible for the trial if they received 100 mg of enteric-coated aspirin daily for more than 3 months for the primary or secondary prevention of cardiovascular and cerebrovascular disease and were found to have more than 3 mucosal breaks (i.e., erosions or ulcers) in the small intestine by capsule endoscopy. Other inclusion criteria were an age of at least 20 years and stable disease with no pressing need to change the current aspirin regimen.</p><p>The main exclusion criteria included diseases that could induce small intestinal injury (such as Crohn&#x02019;s disease, gastrointestinal stromal tumors, and small intestinal tumors), use of NSAIDs or anti-cancer drugs, the presence of diverticula and diaphragm-like stenosis in the small intestine, and severe renal or hepatic dysfunction. Patients were also excluded if they used antibiotics, sulfasalazine, prostaglandin (PG) analogs, corticosteroids, or gastroprotective drugs, as these could potentially heal or worsen LDA-induced small intestinal damage. Patients with ongoing overt gastrointestinal bleeding and those found to have active small intestinal bleeding by VCE were also excluded.</p></sec><sec id="sec013"><title>Assessment</title><p>The primary endpoint was the change in the number of mucosal breaks from baseline to 8 weeks. Secondary endpoints included changes in the LS from baseline to 8 weeks, complete healing of small intestinal mucosal breaks at 8 weeks, and changes in the levels of hemoglobin and serum albumin from baseline to 8 weeks. Safety assessments included the documentation of adverse events and clinical laboratory testing at baseline and after 4 and 8 weeks of treatment.</p></sec><sec id="sec014"><title>Statistical analysis</title><p>Results are expressed as medians and interquartile ranges for continuous variables and percentages for categorical variables. The characteristics of patients in the placebo and rebamipide groups were compared using the &#x003c7;2 test or Fisher exact test for categorical variables, whereas quantitative variables were analyzed by the Mann&#x02013;Whitney <italic>U</italic>-test. The Wilcoxon signed-rank test (for continuous data) or McNemar test (for ordinal data) was used for comparisons of data between baseline and 8 weeks. Differences with P-values &#x0003c;0.05 were considered significant. All statistical analyses were performed using SPSS 21 for Windows (SPSS Inc.; Chicago, Illinois, United States).</p></sec><sec id="sec015"><title>Sample size estimation</title><p>Sample size was estimated based on a previous study showing that the complete healing rate of LDA-induced mucosal breaks was 58% in patients who took misoprostol, a PGE<sub>1</sub> analog, for 8 weeks. The following assumptions were made for sample size calculation: (1) the wound-healing effect of a triple dose of rebamipide was equal to that of misoprostol; (2) the complete healing rates in the placebo and rebamipide groups were 20% and 58%, respectively; (3) 10% of patients in each group will either drop out or have unsatisfactory follow-up VCE images. We calculated that at least 30 patients were needed in the rebamipide group to give the study 90% power at a 5% significance level by a test of proportions.</p></sec></sec><sec sec-type="results" id="sec016"><title>Results</title><sec id="sec017"><title>Subject enrollment and baseline characteristics</title><p>Between February 2011 and January 2014, 125 patients were assessed for study eligibility. In total, 43 patients were enrolled and randomly assigned (in a 2:1 ratio) to the rebamipide group (n = 29) or placebo group (n = 14). The study&#x02019;s participant flow is shown in <xref rid="pone.0122330.g001" ref-type="fig">Fig 1</xref>. Five patients were excluded because of cessation of LDA therapy during the trial (n = 2), incomplete visualization on the second capsule endoscopy (n = 1), patient&#x02019;s intention to withdraw from the trial (n = 1), and the development of overt gastrointestinal bleeding (n = 1).</p><fig id="pone.0122330.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0122330.g001</object-id><label>Fig 1</label><caption><title>Trial flow diagram.</title></caption><graphic xlink:href="pone.0122330.g001"/></fig><p>Regarding gastrointestinal symptoms in the enrolled patients, one patient had abdominal fullness at baseline, while the others were asymptomatic. At 8 weeks of treatment, all patients who completed the trial were asymptomatic.</p><p>The patients&#x02019; baseline clinical characteristics were grouped according to treatment (<xref rid="pone.0122330.t001" ref-type="table">Table 1</xref>). There was no significant difference in baseline characteristics such as age, sex, body mass index, smoking habit, and alcohol consumption between the placebo and rebamipide groups. In addition, the number of mucosal breaks at baseline did not differ between the two groups. Typical photographs of mucosal breaks observed in this study are shown in <xref rid="pone.0122330.g002" ref-type="fig">Fig 2A and 2B</xref>.</p><fig id="pone.0122330.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0122330.g002</object-id><label>Fig 2</label><caption><title>Capsule endoscopic images of small bowel mucosal breaks induced by low-dose enteric-coated aspirin.</title><p>Typical photographs of mucosal breaks observed in this study are shown. A: a mucosal break (arrow). B: multiple mucosal breaks (arrows).</p></caption><graphic xlink:href="pone.0122330.g002"/></fig><table-wrap id="pone.0122330.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0122330.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of patients.</title></caption><alternatives><graphic id="pone.0122330.t001g" xlink:href="pone.0122330.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Placebo (n = 13)</th><th align="left" rowspan="1" colspan="1">Rebamipide (n = 25)</th><th align="left" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age (y)</td><td align="left" rowspan="1" colspan="1">74.8</td><td align="left" rowspan="1" colspan="1">74.1</td><td align="left" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, n (%)</td><td align="left" rowspan="1" colspan="1">9 (69.2)</td><td align="left" rowspan="1" colspan="1">16 (64.0)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking habit, n (%)</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td><td align="left" rowspan="1" colspan="1">4 (16)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol consumption, n (%)</td><td align="left" rowspan="1" colspan="1">4 (30.8)</td><td align="left" rowspan="1" colspan="1">10 (40)</td><td align="left" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Underlying diseases</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ischemic heart disease, n (%)</td><td align="left" rowspan="1" colspan="1">8 (32)</td><td align="left" rowspan="1" colspan="1">15 (60)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">ischemic cerebrovascular disease, n (%)</td><td align="left" rowspan="1" colspan="1">3 (23.1)</td><td align="left" rowspan="1" colspan="1">3 (12)</td><td align="left" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">atherosclerosis, n (%)</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td><td align="left" rowspan="1" colspan="1">4 (16)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">others, n (%)</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td><td align="left" rowspan="1" colspan="1">3 (12)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Complications</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">hypertension, n (%)</td><td align="left" rowspan="1" colspan="1">11 (84.6)</td><td align="left" rowspan="1" colspan="1">20 (80)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">hyperlipidemia, n (%)</td><td align="left" rowspan="1" colspan="1">6 (46.2)</td><td align="left" rowspan="1" colspan="1">12 (48)</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">diabetes mellitus, n (%)</td><td align="left" rowspan="1" colspan="1">3 (27.3)</td><td align="left" rowspan="1" colspan="1">3 (12)</td><td align="left" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Proton pump inhibitor use, n (%)</td><td align="left" rowspan="1" colspan="1">7 (53.8)</td><td align="left" rowspan="1" colspan="1">12 (48)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">H<sub>2</sub> receptor antagonist use, n (%)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">2 (8)</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">Concomitant use of other antiplatelets</td><td align="left" rowspan="1" colspan="1">2 (15.4)</td><td align="left" rowspan="1" colspan="1">3 (12)</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Warfarin use, n (%)</td><td align="left" rowspan="1" colspan="1">1 (7.7)</td><td align="left" rowspan="1" colspan="1">3 (12)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">ARB use, n (%)</td><td align="left" rowspan="1" colspan="1">7 (53.8)</td><td align="left" rowspan="1" colspan="1">12 (48)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin use, n (%)</td><td align="left" rowspan="1" colspan="1">6 (46.2)</td><td align="left" rowspan="1" colspan="1">12 (48)</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Median number of mucosal breaks (IQR)</td><td align="left" rowspan="1" colspan="1">6 (4.0&#x02013;18.5)</td><td align="left" rowspan="1" colspan="1">4 (3.0&#x02013;8.0)</td><td align="left" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Median hemoglobin level (IQR) (g/dL)</td><td align="left" rowspan="1" colspan="1">13.1 (9.6&#x02013;14.1)</td><td align="left" rowspan="1" colspan="1">12.9 (11.3&#x02013;13.6)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Median albumin level (IQR) (g/dL)</td><td align="left" rowspan="1" colspan="1">4 (3.8&#x02013;4.3)</td><td align="left" rowspan="1" colspan="1">4.2 (3.9&#x02013;4.4)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>ARB, angiotensin II receptor blocker; IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>Primary endpoint</title><p>After 8 weeks of treatment, rebamipide significantly reduced the number of mucosal breaks from 4.0 (3.0&#x02013;8.0) to 2.0 (3.0&#x02013;8.0, p = 0.046), whereas placebo did not result in a significant reduction (p = 0.08). The median number of mucosal breaks in the placebo group was 6.0 (4.0&#x02013;18.5) at baseline and 3.0 (2.0&#x02013;15.0) at 8 weeks (<xref rid="pone.0122330.g003" ref-type="fig">Fig 3</xref>).</p><fig id="pone.0122330.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0122330.g003</object-id><label>Fig 3</label><caption><title>Changes in the number of small intestinal mucosal breaks from baseline to posttreatment.</title><p>Results were analyzed by the Wilcoxon signed-rank test.</p></caption><graphic xlink:href="pone.0122330.g003"/></fig></sec><sec id="sec019"><title>Secondary endpoints</title><p>Rebamipide treatment significantly improved the severity of intestinal damage as assessed by the LS (p = 0.02), whereas placebo treatment did not alter the LS (p = 0.32, <xref rid="pone.0122330.g004" ref-type="fig">Fig 4</xref>). Eight (32%) of 25 patients in the rebamipide group achieved complete healing of the intestinal mucosal breaks at 8 weeks of treatment, compared with 1 (7.7%) of 13 patients in the placebo group. The complete healing rate in the rebamipide group was higher than that in the placebo group, although the difference did not reach statistical significance (p = 0.13). Neither group showed significant changes from baseline to 8 weeks in hemoglobin and serum albumin levels (<xref rid="pone.0122330.t002" ref-type="table">Table 2</xref>).</p><fig id="pone.0122330.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0122330.g004</object-id><label>Fig 4</label><caption><title>Changes in the severity of small intestinal mucosal breaks from baseline to posttreatment.</title><p>Results were analyzed by McNemar test.</p></caption><graphic xlink:href="pone.0122330.g004"/></fig><table-wrap id="pone.0122330.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0122330.t002</object-id><label>Table 2</label><caption><title>Changes in the levels of hemoglobin and albumin after treatment with placebo or rebamipide.</title></caption><alternatives><graphic id="pone.0122330.t002g" xlink:href="pone.0122330.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Baseline</th><th align="left" rowspan="1" colspan="1">After treatment</th><th colspan="2" align="center" rowspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">Median hemoglobin level (IQR) (g/dL)</td><td colspan="2" align="left" rowspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">13.1 (9.6&#x02013;14.1)</td><td colspan="2" align="left" rowspan="1">13.1 (11.0&#x02013;14.1)</td><td align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">Rebamipide</td><td align="left" rowspan="1" colspan="1">12.9 (11.3&#x02013;13.6)</td><td colspan="2" align="left" rowspan="1">13.2 (11.8&#x02013;14.1)</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Median albumin level (IQR) (g/dL)</td><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">4.0 (3.8&#x02013;4.3)</td><td colspan="2" align="left" rowspan="1">4.1(3.9&#x02013;4.2)</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Rebamipide</td><td align="left" rowspan="1" colspan="1">4.2 (3.9&#x02013;4.4)</td><td colspan="2" align="left" rowspan="1">4.2 (4.1&#x02013;4.3)</td><td align="left" rowspan="1" colspan="1">0.77</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Results are expressed as medians and interquartile ranges (IQRs)</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec020"><title>Safety</title><p>Significant changes from the baseline values of any of the examined laboratory parameters were recorded in both groups of patients. As described above, one patient in the placebo group developed overt gastrointestinal bleeding and discontinued the intervention (<xref rid="pone.0122330.g001" ref-type="fig">Fig 1</xref>); no other adverse events were reported.</p></sec></sec><sec sec-type="conclusions" id="sec021"><title>Discussion</title><p>Recent studies demonstrated the efficacy of several drugs such as rebamipide [<xref rid="pone.0122330.ref012" ref-type="bibr">12</xref>], misoprostol [<xref rid="pone.0122330.ref004" ref-type="bibr">4</xref>] and a probiotic preparation, <italic>Lactobacillus casei</italic> strain Shirota [<xref rid="pone.0122330.ref007" ref-type="bibr">7</xref>], for LDA-induced enteropathy. However, these studies had shortcomings in terms of the subjects included. Some studies were conducted in young, healthy volunteers and evaluated preventive effects on LDA-induced small intestinal damage. Even those studies that evaluated healing effects in chronic LDA users enrolled patients with red spots but no mucosal breaks or patients with very few mucosal breaks thought to be clinically insignificant. Furthermore, few randomized, double-blind, placebo-controlled trials assessing the efficacy of treatments for LDA-induced intestinal damage have been reported. In this study, we demonstrated that treatment with triple-dose rebamipide could be effective therapy for LDA-induced enteropathy in patients who had more than 3 mucosal breaks, and that this dose of rebamipide was well tolerated and did not cause any adverse events. To the best of our knowledge, rebamipide is the first drug to show efficacy for the treatment of LDA-induced moderate-to-severe enteropathy.</p><p>Recent studies greatly improved our understanding of the mechanisms underlying the pathogenesis of NSAID (including LDA)-induced small bowel damage. A mechanism of primary importance for the onset of this damage is the inhibition of cyclooxygenase by NSAIDs, which leads to collapse of the mucosal defensive system due to a reduction in PG synthesis. In addition, the topical effect of NSAIDs on the small bowel epithelium causes mitochondrial dysfunction, which also contributes to the disturbance of barrier function [<xref rid="pone.0122330.ref015" ref-type="bibr">15</xref>]. Once the mucosal barrier has been disrupted, luminal Gram-negative bacteria enter the epithelium and release lipopolysaccharide [<xref rid="pone.0122330.ref016" ref-type="bibr">16</xref>], resulting in the induction of mucosal inflammatory responses such as cytokine overexpression via the activation of the innate immune system [<xref rid="pone.0122330.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0122330.ref019" ref-type="bibr">19</xref>]. This phenomenon then triggers neutrophil infiltration with subsequent release of tissue proteolytic enzymes and reactive oxygen species, leading to intestinal ulceration.</p><p>Therefore, agents that interfere with any phase of the development of the damage are thought to be useful in treating enteropathy [<xref rid="pone.0122330.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0122330.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0122330.ref021" ref-type="bibr">21</xref>]. Rebamipide has various effects on the gastrointestinal tract [<xref rid="pone.0122330.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0122330.ref022" ref-type="bibr">22</xref>], which explains its efficacy against LDA- or NSAID-induced small intestinal damage. It increases PG concentration via the induction of cyclooxygenase-2 [<xref rid="pone.0122330.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0122330.ref024" ref-type="bibr">24</xref>] and has the potential to inhibit inflammatory cytokine expression [<xref rid="pone.0122330.ref025" ref-type="bibr">25</xref>] and neutrophil infiltration [<xref rid="pone.0122330.ref026" ref-type="bibr">26</xref>]. Rebamipide can also scavenge reactive oxygen species [<xref rid="pone.0122330.ref027" ref-type="bibr">27</xref>] and prevent indomethacin-induced mitochondrial damage in cultured gastric cells [<xref rid="pone.0122330.ref028" ref-type="bibr">28</xref>]. Furthermore, recent experimental studies showed that rebamipide regulates small intestinal microbiota via the induction of antimicrobial peptides [<xref rid="pone.0122330.ref029" ref-type="bibr">29</xref>, <xref rid="pone.0122330.ref030" ref-type="bibr">30</xref>]. Thus, these effects of rebamipide appear to act in concert to prevent and heal enteropathy.</p><p>There are a few limitations to this study. First, the sample size is relatively small. We therefore failed to find a significant difference in the complete healing rate of mucosal breaks between the rebamipide and placebo groups, although we successfully demonstrated the efficacy of rebamipide in terms of the primary endpoint (i.e., reduction in the number of mucosal breaks). The sample size of this trial was calculated based on our previous study in which treatment with misoprostol resulted in complete healing in 58% of patients with LDA-induced small intestinal mucosal breaks [<xref rid="pone.0122330.ref004" ref-type="bibr">4</xref>]. However, that study did not exclude patients with 1 or 2 mucosal breaks. As mentioned previously, we excluded such patients and enrolled only patients with more than 3 mucosal breaks, which may have reduced the complete healing rate in this study. Further studies involving larger sample sizes are needed to determine the efficacy of rebamipide for achieving complete healing of moderate-to-severe enteropathy. The second limitation is our exclusion of patients with active small intestinal bleeding, which is a clinically important condition. Therefore, a clinical trial that includes such patients should be performed next. The other limitation is that we cannot deny the possibility that VCE missed some intestinal lesions because the LDA-induced small intestinal mucosal breaks were relatively small. A large-scale trial would be required to decrease the effect of this limitation.</p><p>In conclusion, triple-dose rebamipide is effective in the treatment of LDA-induced moderate-to-severe enteropathy, and is well tolerated and safe. Since our study does not repudiate the efficacy of standard dose rebamipide, a comparative study of standard and triple-dose rebamipide is needed to determine the appropriate dose of this drug for the treatment of LDA-induced clinically significant small intestinal damage.</p></sec><sec sec-type="supplementary-material" id="sec022"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0122330.s001"><label>S1 CONSORT Checklist</label><caption><title>CONSORT Checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0122330.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0122330.s002"><label>S1 Protocol</label><caption><title>Trial Protocol.</title><p>(DOC)</p></caption><media xlink:href="pone.0122330.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0122330.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Ogawa</surname><given-names>H</given-names></name>, <name><surname>Nakayama</surname><given-names>M</given-names></name>, <name><surname>Morimoto</surname><given-names>T</given-names></name>, <name><surname>Uemura</surname><given-names>S</given-names></name>, <name><surname>Kanauchi</surname><given-names>M</given-names></name>, <name><surname>Doi</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>300</volume>: <fpage>2134</fpage>&#x02013;<lpage>2141</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2008.623">10.1001/jama.2008.623</ext-link></comment>
<pub-id pub-id-type="pmid">18997198</pub-id></mixed-citation></ref><ref id="pone.0122330.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Cook</surname><given-names>NR</given-names></name>, <name><surname>Lee</surname><given-names>IM</given-names></name>, <name><surname>Gordon</surname><given-names>D</given-names></name>, <name><surname>Gaziano</surname><given-names>JM</given-names></name>, <name><surname>Manson</surname><given-names>JE</given-names></name>, <etal>et al</etal>
<article-title>A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>: <fpage>1293</fpage>&#x02013;<lpage>1304</lpage>.
<pub-id pub-id-type="pmid">15753114</pub-id></mixed-citation></ref><ref id="pone.0122330.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Xie</surname><given-names>M</given-names></name>, <name><surname>Shan</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>S</given-names></name>, <name><surname>Yang</surname><given-names>W</given-names></name>, <name><surname>Bao</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>: <fpage>e90286</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0090286">10.1371/journal.pone.0090286</ext-link></comment>
<pub-id pub-id-type="pmid">25360605</pub-id></mixed-citation></ref><ref id="pone.0122330.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Sugimori</surname><given-names>S</given-names></name>, <name><surname>Kameda</surname><given-names>N</given-names></name>, <name><surname>Machida</surname><given-names>H</given-names></name>, <name><surname>Okazaki</surname><given-names>H</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2008</year>;<volume>6</volume>: <fpage>1279</fpage>&#x02013;<lpage>1282</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cgh.2008.06.021">10.1016/j.cgh.2008.06.021</ext-link></comment>
<pub-id pub-id-type="pmid">18995219</pub-id></mixed-citation></ref><ref id="pone.0122330.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Smecuol</surname><given-names>E</given-names></name>, <name><surname>Pinto</surname><given-names>Sanchez MI</given-names></name>, <name><surname>Suarez</surname><given-names>A</given-names></name>, <name><surname>Argonz</surname><given-names>JE</given-names></name>, <name><surname>Sugai</surname><given-names>E</given-names></name>, <name><surname>Vazquez</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2009</year>;<volume>7</volume>: <fpage>524</fpage>&#x02013;<lpage>529</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cgh.2008.12.019">10.1016/j.cgh.2008.12.019</ext-link></comment>
<pub-id pub-id-type="pmid">19249402</pub-id></mixed-citation></ref><ref id="pone.0122330.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Nadatani</surname><given-names>Y</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Sogawa</surname><given-names>M</given-names></name>, <name><surname>Yamagami</surname><given-names>H</given-names></name>, <name><surname>Shiba</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Incidence and risk factors of gastrointestinal bleeding in patients on low-dose aspirin therapy after percutaneous coronary intervention in Japan</article-title>. <source>Scand J Gastroenterol</source>. <year>2013</year>;<volume>48</volume>: <fpage>320</fpage>&#x02013;<lpage>325</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/00365521.2012.758771">10.3109/00365521.2012.758771</ext-link></comment>
<pub-id pub-id-type="pmid">23298342</pub-id></mixed-citation></ref><ref id="pone.0122330.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Endo</surname><given-names>H</given-names></name>, <name><surname>Higurashi</surname><given-names>T</given-names></name>, <name><surname>Hosono</surname><given-names>K</given-names></name>, <name><surname>Sakai</surname><given-names>E</given-names></name>, <name><surname>Sekino</surname><given-names>Y</given-names></name>, <name><surname>Iida</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study</article-title>. <source>J Gastroenterol</source>. <year>2011</year>;<volume>46</volume>: <fpage>894</fpage>&#x02013;<lpage>905</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00535-011-0410-1">10.1007/s00535-011-0410-1</ext-link></comment>
<pub-id pub-id-type="pmid">21556830</pub-id></mixed-citation></ref><ref id="pone.0122330.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Watari</surname><given-names>I</given-names></name>, <name><surname>Oka</surname><given-names>S</given-names></name>, <name><surname>Tanaka</surname><given-names>S</given-names></name>, <name><surname>Aoyama</surname><given-names>T</given-names></name>, <name><surname>Imagawa</surname><given-names>H</given-names></name>, <name><surname>Shishido</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study</article-title>. <source>BMC Gastroenterol</source>. <year>2013</year>;<volume>13</volume>: <fpage>108</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-230X-13-108">10.1186/1471-230X-13-108</ext-link></comment>
<pub-id pub-id-type="pmid">23826914</pub-id></mixed-citation></ref><ref id="pone.0122330.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Arakawa</surname><given-names>T</given-names></name>, <name><surname>Higuchi</surname><given-names>K</given-names></name>, <name><surname>Fujiwara</surname><given-names>Y</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Tominaga</surname><given-names>K</given-names></name>, <name><surname>Sasaki</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications</article-title>. <source>Dig Dis Sci</source>. <year>2005</year>;<volume>50</volume>
<issue>Suppl 1</issue>: <fpage>S3</fpage>&#x02013;<lpage>S11</lpage>.
<pub-id pub-id-type="pmid">16184418</pub-id></mixed-citation></ref><ref id="pone.0122330.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Park</surname><given-names>SH</given-names></name>, <name><surname>Cho</surname><given-names>CS</given-names></name>, <name><surname>Lee</surname><given-names>OY</given-names></name>, <name><surname>Jun</surname><given-names>JB</given-names></name>, <name><surname>Lin</surname><given-names>SR</given-names></name>, <name><surname>Zhou</surname><given-names>LY</given-names></name>, <etal>et al</etal>
<article-title>Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY</article-title>. <source>J Clin Biochem Nutr</source>. <year>2007</year>;<volume>40</volume>: <fpage>148</fpage>&#x02013;<lpage>155</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3164/jcbn.40.148">10.3164/jcbn.40.148</ext-link></comment>
<pub-id pub-id-type="pmid">18188417</pub-id></mixed-citation></ref><ref id="pone.0122330.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Niwa</surname><given-names>Y</given-names></name>, <name><surname>Nakamura</surname><given-names>M</given-names></name>, <name><surname>Ohmiya</surname><given-names>N</given-names></name>, <name><surname>Maeda</surname><given-names>O</given-names></name>, <name><surname>Ando</surname><given-names>T</given-names></name>, <name><surname>Itoh</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study</article-title>. <source>J Gastroenterol</source>. <year>2008</year>;<volume>43</volume>: <fpage>270</fpage>&#x02013;<lpage>276</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00535-007-2155-4">10.1007/s00535-007-2155-4</ext-link></comment>
<pub-id pub-id-type="pmid">18458842</pub-id></mixed-citation></ref><ref id="pone.0122330.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Mizukami</surname><given-names>K</given-names></name>, <name><surname>Murakami</surname><given-names>K</given-names></name>, <name><surname>Abe</surname><given-names>T</given-names></name>, <name><surname>Inoue</surname><given-names>K</given-names></name>, <name><surname>Uchida</surname><given-names>M</given-names></name>, <name><surname>Okimoto</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Aspirin-induced small bowel injuries and the preventive effect of rebamipide</article-title>. <source>World J Gastroenterol</source>. <year>2011</year>;<volume>17</volume>: <fpage>5117</fpage>&#x02013;<lpage>5122</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3748/wjg.v17.i46.5117">10.3748/wjg.v17.i46.5117</ext-link></comment>
<pub-id pub-id-type="pmid">22171147</pub-id></mixed-citation></ref><ref id="pone.0122330.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Akamatsu</surname><given-names>T</given-names></name>, <name><surname>Nakamura</surname><given-names>N</given-names></name>, <name><surname>Furuya</surname><given-names>N</given-names></name>, <name><surname>Shimizu</surname><given-names>T</given-names></name>, <name><surname>Gotou</surname><given-names>A</given-names></name>, <name><surname>Kiyosawa</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers</article-title>. <source>Dig Dis Sci</source>. <year>2002</year>;<volume>47</volume>: <fpage>1399</fpage>&#x02013;<lpage>1404</lpage>.
<pub-id pub-id-type="pmid">12064818</pub-id></mixed-citation></ref><ref id="pone.0122330.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Gralnek</surname><given-names>IM</given-names></name>, <name><surname>Defranchis</surname><given-names>R</given-names></name>, <name><surname>Seidman</surname><given-names>E</given-names></name>, <name><surname>Leighton</surname><given-names>JA</given-names></name>, <name><surname>Legnani</surname><given-names>P</given-names></name>, <name><surname>Lewis</surname><given-names>BS</given-names></name>. <article-title>Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2008</year>;<volume>27</volume>: <fpage>146</fpage>&#x02013;<lpage>154</lpage>.
<pub-id pub-id-type="pmid">17956598</pub-id></mixed-citation></ref><ref id="pone.0122330.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Ohkawa</surname><given-names>F</given-names></name>, <name><surname>Nadatani</surname><given-names>Y</given-names></name>, <name><surname>Otani</surname><given-names>K</given-names></name>, <name><surname>Machida</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase</article-title>. <source>J Clin Biochem Nutr</source>. <year>2011</year>;<volume>48</volume>: <fpage>149</fpage>&#x02013;<lpage>153</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3164/jcbn.10-75">10.3164/jcbn.10-75</ext-link></comment>
<pub-id pub-id-type="pmid">21373268</pub-id></mixed-citation></ref><ref id="pone.0122330.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Higuchi</surname><given-names>K</given-names></name>, <name><surname>Kobata</surname><given-names>A</given-names></name>, <name><surname>Nishio</surname><given-names>H</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Shiba</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent</article-title>. <source>Gut</source>. <year>2008</year>;<volume>57</volume>: <fpage>181</fpage>&#x02013;<lpage>187</lpage>.
<pub-id pub-id-type="pmid">17639086</pub-id></mixed-citation></ref><ref id="pone.0122330.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Higuchi</surname><given-names>K</given-names></name>, <name><surname>Umegaki</surname><given-names>E</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Yoda</surname><given-names>Y</given-names></name>, <name><surname>Morita</surname><given-names>E</given-names></name>, <name><surname>Murano</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Present status and strategy of NSAIDs-induced small bowel injury</article-title>. <source>J Gastroenterol</source>. <year>2009</year>;<volume>44</volume>: <fpage>879</fpage>&#x02013;<lpage>888</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00535-009-0102-2">10.1007/s00535-009-0102-2</ext-link></comment>
<pub-id pub-id-type="pmid">19568687</pub-id></mixed-citation></ref><ref id="pone.0122330.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Arakawa</surname><given-names>T</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Tominaga</surname><given-names>K</given-names></name>, <name><surname>Otani</surname><given-names>K</given-names></name>, <name><surname>Nadatani</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Small intestinal injury caused by NSAIDs/aspirin: finding new from old</article-title>. <source>Curr Med Chem</source>. <year>2012</year>;<volume>19</volume>: <fpage>77</fpage>&#x02013;<lpage>81</lpage>.
<pub-id pub-id-type="pmid">22300079</pub-id></mixed-citation></ref><ref id="pone.0122330.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Nadatani</surname><given-names>Y</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Machida</surname><given-names>H</given-names></name>, <name><surname>Okazaki</surname><given-names>H</given-names></name>, <name><surname>Yamagami</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4</article-title>. <source>Am J Pathol</source>. <year>2012</year>;<volume>181</volume>: <fpage>98</fpage>&#x02013;<lpage>110</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ajpath.2012.03.039">10.1016/j.ajpath.2012.03.039</ext-link></comment>
<pub-id pub-id-type="pmid">22634181</pub-id></mixed-citation></ref><ref id="pone.0122330.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Nishio</surname><given-names>H</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Yamagami</surname><given-names>H</given-names></name>, <name><surname>Okazaki</surname><given-names>H</given-names></name>, <name><surname>Watanabe</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2009</year>;<volume>297</volume>: <fpage>G506</fpage>&#x02013;<lpage>513</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpgi.90553.2008">10.1152/ajpgi.90553.2008</ext-link></comment>
<pub-id pub-id-type="pmid">19589943</pub-id></mixed-citation></ref><ref id="pone.0122330.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Shiba</surname><given-names>M</given-names></name>, <name><surname>Nadatani</surname><given-names>Y</given-names></name>, <name><surname>Nagami</surname><given-names>Y</given-names></name>, <name><surname>Sugimori</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients</article-title>. <source>Gut</source>. <year>2014</year>;<volume>63</volume>: <fpage>409</fpage>&#x02013;<lpage>414</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/gutjnl-2013-304713">10.1136/gutjnl-2013-304713</ext-link></comment>
<pub-id pub-id-type="pmid">23697473</pub-id></mixed-citation></ref><ref id="pone.0122330.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Naito</surname><given-names>Y</given-names></name>, <name><surname>Yoshikawa</surname><given-names>T</given-names></name>. <article-title>Rebamipide: a gastrointestinal protective drug with pleiotropic activities</article-title>. <source>Expert Rev Gastroenterol Hepatol</source>. <year>2010</year>;<volume>4</volume>: <fpage>261</fpage>&#x02013;<lpage>270</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1586/egh.10.25">10.1586/egh.10.25</ext-link></comment>
<pub-id pub-id-type="pmid">20528113</pub-id></mixed-citation></ref><ref id="pone.0122330.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Higuchi</surname><given-names>K</given-names></name>, <name><surname>Taira</surname><given-names>K</given-names></name>, <name><surname>Sasaki</surname><given-names>E</given-names></name>, <name><surname>Shiba</surname><given-names>M</given-names></name>, <name><surname>Tominaga</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice</article-title>. <source>Dig Dis Sci</source>. <year>2005</year>;<volume>50</volume>
<issue>Suppl 1</issue>: <fpage>S63</fpage>&#x02013;<lpage>69</lpage>.
<pub-id pub-id-type="pmid">16184423</pub-id></mixed-citation></ref><ref id="pone.0122330.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Sun</surname><given-names>WH</given-names></name>, <name><surname>Tsuji</surname><given-names>S</given-names></name>, <name><surname>Tsujii</surname><given-names>M</given-names></name>, <name><surname>Gunawan</surname><given-names>ES</given-names></name>, <name><surname>Kawai</surname><given-names>N</given-names></name>, <name><surname>Kimura</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2000</year>;<volume>295</volume>: <fpage>447</fpage>&#x02013;<lpage>452</lpage>.
<pub-id pub-id-type="pmid">11046075</pub-id></mixed-citation></ref><ref id="pone.0122330.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Aihara</surname><given-names>M</given-names></name>, <name><surname>Imagawa</surname><given-names>K</given-names></name>, <name><surname>Funakoshi</surname><given-names>Y</given-names></name>, <name><surname>Ohmoto</surname><given-names>Y</given-names></name>, <name><surname>Kikuchi</surname><given-names>M</given-names></name>. <article-title>Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells</article-title>. <source>Dig Dis Sci</source>. <year>1998</year>;<volume>43</volume>: <fpage>160S</fpage>&#x02013;<lpage>166S</lpage>.
<pub-id pub-id-type="pmid">9753244</pub-id></mixed-citation></ref><ref id="pone.0122330.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Higuchi</surname><given-names>K</given-names></name>, <name><surname>Hamaguchi</surname><given-names>M</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Wada</surname><given-names>R</given-names></name>, <name><surname>Tominaga</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori infection in Mongolian gerbils</article-title>. <source>Dig Dis Sci</source>. <year>2002</year>;<volume>47</volume>: <fpage>1582</fpage>&#x02013;<lpage>1589</lpage>.
<pub-id pub-id-type="pmid">12141820</pub-id></mixed-citation></ref><ref id="pone.0122330.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Yoshikawa</surname><given-names>T</given-names></name>, <name><surname>Naito</surname><given-names>Y</given-names></name>, <name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Kondo</surname><given-names>M</given-names></name>. <article-title>Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance</article-title>. <source>Arzneimittelforschung</source>. <year>1993</year>;<volume>43</volume>: <fpage>363</fpage>&#x02013;<lpage>366</lpage>.
<pub-id pub-id-type="pmid">8387788</pub-id></mixed-citation></ref><ref id="pone.0122330.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Nagano</surname><given-names>Y</given-names></name>, <name><surname>Matsui</surname><given-names>H</given-names></name>, <name><surname>Muramatsu</surname><given-names>M</given-names></name>, <name><surname>Shimokawa</surname><given-names>O</given-names></name>, <name><surname>Shibahara</surname><given-names>T</given-names></name>, <name><surname>Yanaka</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells</article-title>. <source>Dig Dis Sci</source>. <year>2005</year>;<volume>50</volume>
<issue>Suppl 1</issue>: <fpage>S76</fpage>&#x02013;<lpage>83</lpage>.
<pub-id pub-id-type="pmid">16184425</pub-id></mixed-citation></ref><ref id="pone.0122330.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Imaeda</surname><given-names>H</given-names></name>, <name><surname>Fujimoto</surname><given-names>T</given-names></name>, <name><surname>Takahashi</surname><given-names>K</given-names></name>, <name><surname>Kasumi</surname><given-names>E</given-names></name>, <name><surname>Fujiyama</surname><given-names>Y</given-names></name>, <name><surname>Andoh</surname><given-names>A</given-names></name>. <article-title>Terminal-restriction fragment length polymorphism (T-RFLP) analysis for changes in the gut microbiota profiles of indomethacin- and rebamipide-treated mice</article-title>. <source>Digestion</source>. <year>2012</year>;<volume>86</volume>: <fpage>250</fpage>&#x02013;<lpage>257</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000341508">10.1159/000341508</ext-link></comment>
<pub-id pub-id-type="pmid">22964750</pub-id></mixed-citation></ref><ref id="pone.0122330.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Tanigawa</surname><given-names>T</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Otani</surname><given-names>K</given-names></name>, <name><surname>Nadatani</surname><given-names>Y</given-names></name>, <name><surname>Ohkawa</surname><given-names>F</given-names></name>, <name><surname>Sogawa</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of alpha-defensin 5</article-title>. <source>Eur J Pharmacol</source>. <year>2013</year>;<volume>704</volume>: <fpage>64</fpage>&#x02013;<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejphar.2013.02.010">10.1016/j.ejphar.2013.02.010</ext-link></comment>
<pub-id pub-id-type="pmid">23428631</pub-id></mixed-citation></ref></ref-list></back></article>